Table 2. Survival according to RUNX1 expression in the testing group of 157 CN-AML patients.

Outcome	All patients, n = 157			ELN Favorable category			ELN Intermediate-I category
	RUNX1high, n = 78	RUNX1low, n = 79	P	RUNX1high, n = 17	RUNX1low, n = 18	P	RUNX1high, n = 65	RUNX1low, n = 57	P
OS
Median OS, m	10.46 (0.07–198.7)	37.03 (0.13–214.5)	0.009	58.91 (0.59–169.5)	38.34 (0.3–214.5)	0.65	8.41 (0.07–198.7)	35.91 (0.13–190.3)	0.002
Estimated OS at 3 y. % (95% CI)	0.33 (0.24–0.46)	0.54 (0.45–0.67)	0.01	0.65 (0.46–0.92)	0.56 (0.37–0.84)	0.73	0.25 (0.16–0.38)	0.54 (0.43–0.68)	0.007
EFS
Median EFS, m	7.1 (0.03–198.7)	17.81 (0.03–214.5)	0.011	39.82 (0.03–169.5)	33.03 (0.03–214.5)	0.36	6.57 (0.03–198.7)	15.54 (0.03–190.3)	0.004
Estimated EFS at 3 y. % (95% CI)	0.28 (0.2–0.4)	0.41 (0.31–0.53)	0.005	0.53 (0.34–0.83)	0.56 (0.37–0.84)	0.17	0.2 (0.12–0.33)	0.38 (0.27–0.52)	0.03

CI, confidence interval.